 - Younger adult patients with previously untreated high-risk disease complex karyotype, inv3 or t3;3, t6;9, monosomal karyotype, therapy-related and secondary disease that are unwilling to undergo or not candidates for conventional induction chemotherapy with cytarabineanthracyclines andor allogeneic stem cell transplantation 